Navigation Links
Drug Combinations That May Cause Major Drug Interactions Common Among Seniors Who Take Antidepressants, According to Thomson Reuters Research
Date:12/17/2010

ANN ARBOR, Mich., Dec. 17, 2010 /PRNewswire/ -- More than half of older Americans who were prescribed antidepressants for the first time were already taking a medication that could adversely interact with the antidepressant, according to a new study from Thomson Reuters.

For one-fourth of the seniors in the study, these were potentially major drug interactions.

The research, published by the American Journal for Geriatric Psychiatry, illustrates the complexity and challenges of prescribing antidepressants to older patients.

"We found a concerning degree of potentially harmful drug combinations being prescribed to seniors," said Tami Mark, Ph.D., the paper's lead author and director of analytic strategies at Thomson Reuters.

Among the 39,512 new antidepressant users in the study, 25.4 percent were prescribed antidepressants and another medication that could cause a major interaction. An additional 36.1 percent had potential moderate interactions and 38.5 percent had minor or no interactions.

Pain medications were most often identified as having the potential for major interactions with antidepressants, accounting for more than one quarter of all potential major interactions among seniors in the study.

"These findings reinforce the need for clinicians to be aware of potential drug-drug interactions and the importance of close patients monitoring," Mark said.

The presence of contraindications or interactions increased the probability of patients switching antidepressants by 19.5 percent.  

The study also found that 5.6 percent of study subjects had a documented side effect from the antidepressants they were prescribed, most often insomnia, somnolence and drowsiness. Overall, the presence of a side effect was associated with a 4.7 percentage point increase in drug switching (from 16.5% to 21.7%) and a 3.7 percentage point increase in discontinuation of treatment (from 22% to 25.7%).

Data for the study were derived from the Thomson Reuters MarketScan® database of Medicare claims. Potential drug interactions were identified using Thomson Reuters DRUG-REAX® System. Study subjects, who were aged 65 years or older, were new antidepressant users who were diagnosed with depression between July 1, 2001, and December 31, 2006.  

The study was funded by Sanofi Aventis. Co-authors include Vijay N. Joish, Ph.D., now with Bayer Pharmaceuticals; Joel W. Hay, Ph.D, from the University of Southern California School of Pharmacy; and David V. Sheehan, M.D., M.B.A., from the University of South Florida College of Medicine.

An abstract is available here: http://journals.lww.com/ajgponline/Abstract/publishahead/Antidepressant_Use_in_Geriatric_Populations__The.99747.aspx

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization.  With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries.  For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
2. Global Partners Join Forces to Speed Development of New TB Drug Combinations
3. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
4. Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
5. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
6. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
7. Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia®
8. Survey Reveals Majority of Americans Hold onto Myths About What Causes Colds and How to Treat Them
9. HART Health: Headaches Cause More Than $61 Billion a Year in Lost Time
10. American Association for Respiratory Care (AARC) Joins DRIVE4COPD to Raise Awareness of Nations 4th Leading Cause of Death
11. Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 ... Size, Share, Development, Growth and Demand Forecast to 2022 ... Insulin Pump and Others)" published by P&S Market Research, ... $9,998.3 million in 2015, and it is expected to ... on type, the insulin pump segment is expected to ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment of ... doses of biotin in progressive multiple sclerosis: extension phase results ... Ayman Tourbah , Principal Investigator of the Phase 3 study, ... (EAN) in Copenhagen, Denmark . The oral ... Sunday, 29 May 2016 from 14:45 to 16:15 CEST in ...
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... In response to meager ... are unaware of the plight of aphasia. In collaboration with the American Aphasia ... campaign. , The link between stroke and aphasia is relatively unknown, but through ...
(Date:5/27/2016)... ... 27, 2016 , ... With a team of certified experts, ... Aside from its GMP accreditation, Validation Center is also a registered authority of ... and staff. , Validation Center is ISO17025 accredited and only offers its clients ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, ... members and suppliers for its inaugural Member Conference at the Paris Hotel in ... elevating the operational health of America’s healthcare providers. , The conference was highlighted ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... has a significant negative impact on long-term patient survival, reports a team of ... published online this week in the Journal of Thoracic and Cardiovascular Surgery, provide ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey ... , The 550 employees of Sun Health Senior Living (SHSL) may not ... reduces their doctor and prescription copays for the year, while holding the line on ...
Breaking Medicine News(10 mins):